HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EC’s hair-dye mission continues

This article was originally published in The Rose Sheet

Executive Summary

European Commission is requesting opinion from its Scientific Committee on Consumer Products regarding a December 2007 position paper from the European Cosmetics Association (Colipa) related to reaction products formed in the use of permanent hair dyes. In a previous opinion, SCCP considered a Colipa report suggesting that oxidative hair dye reaction products pose no or negligible risks to human health and determined the study insufficient because it covered a limited number of ingredient combinations (11) and used a cream base that contained "only basic ingredients" and therefore was not representative of marketplace (1"The Rose Sheet" Feb. 20, 2006, p. 10). In light of new Colipa submission, EC asks SCCP whether further testing with regard to potential mutagenicity and carcinogenicity of intermediates and reaction products is needed. Evaluation of reaction products is third step in overall strategy adopted by EC to regulate hair-dye substances following impact of 2001 study linking permanent hair dye use to bladder cancer. Separately EC requests that SCCP weigh in on data submitted for new hair dye substance 2-Amino-5-ethylphenol HCl

You may also be interested in...

EU Scientific Committee Reviews Oxidative Hair Dyes, Henna

Additional mutagenicty data is needed to assess the safety of the hair dye ingredient henna, the European Commission Scientific Committee on Consumer Products concludes in a recent opinion

Switzerland Provides Gateway Into Mainland Europe For BASF’s Hepacor

With the Swiss launch of its Non-Alcoholic Fatty Liver Disease supplement, BASF is looking to make inroads into continental Europe. 

Orchard’s Gene Therapy Under Fast-Track Review At EMA

A handful of new products are under review at the European Medicines Agency. Orchard Therapeutics' gene therapy application will be fast-tracked; Roche's filing for its new flu treatment will not.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts